Foundations

Food noise: what it is, and what changes on Mounjaro or Ozempic

Dr Ong Jin Khang · MMC 45245 · LCP holder · The Retreat Clinic, Setia Alam

Food noise is a popular term for persistent, intrusive thoughts about food that a person finds unwanted. Researchers have only begun to define and measure it, using a five-item questionnaire published in 2025. In trials, semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro) reduced cravings, hunger and reactivity to food, and surveys of people on semaglutide report less food noise. The trials so far measured cravings and hunger rather than food noise itself. It is not an eating disorder, though it can overlap with one. This article sets out what is known, what is a survey and what is a trial, and when to see a doctor or psychologist.

Watercolour and ink: an old wooden radio on a windowsill shelf, its tuning needle resting between stations; grey washes and scribbled pencil lines on the left fade to clear paper on the right. Illustration, not a photograph.

Food noise has a name now. The evidence behind the name is still being built.

On this page
  1. What is food noise?
  2. How do researchers define and measure it?
  3. Why do Mounjaro and Ozempic seem to quieten it?
  4. What happens when the medicine stops?
  5. Is food noise an eating disorder?
  6. Who decides, and how are these medicines obtained?
  7. The honest complication

What is food noise?

Food noise is the popular name for thoughts about food that keep arriving without being asked: what to eat next, whether to eat, what was eaten, when the next meal is. Most people think about food, and that is ordinary. The phrase describes thoughts that feel persistent, intrusive and unwelcome, enough to take up attention and sometimes to distress.

It began as a patient and clinician word, not a medical term. Hayashi and colleagues, writing in Nutrients in 2023, noted anecdotal reports from patients and clinicians of less rumination and preoccupation with food on semaglutide, and set out to ask what the phrase might mean in research terms. Their answer links it to food cue reactivity: how loudly the brain responds when food is seen, smelled or remembered.

How do researchers define and measure it?

A 2025 paper in Nutrition and Diabetes offers a working definition: persistent thoughts about food that the person finds unwanted or distressing and that may cause harm, set apart from routine food thoughts by intensity and intrusiveness, resembling rumination. The same paper says a formal clinical definition and a method of measurement were lacking.

The measuring tool is newer still. The Food Noise Questionnaire, published in Obesity in 2025, has five items and was tested in 400 participants. It showed high internal consistency and good repeatability a week later, and it behaved like existing measures of preoccupation with food. Its authors state that its clinical usefulness still needs study. Commentaries in 2026 go further: the evidence on what food noise is, what causes it and whether it differs from cravings and food preoccupation is limited, and there is a risk of turning a common human experience into a condition.

Why do Mounjaro and Ozempic seem to quieten it?

The trial evidence is on neighbouring outcomes. In a double-blind trial of 72 adults, semaglutide 2.4 mg for 20 weeks cut the amount eaten at a test lunch by 35% and, on the Control of Eating Questionnaire, brought better control of eating and fewer, weaker cravings. In STEP 5, a 104-week trial, craving control stayed better on semaglutide at weeks 20, 52 and 104 in a subgroup of 88 people, though the statistics were not corrected for multiple testing.

For tirzepatide, a six-week phase 1 trial in 114 adults found lower appetite, cravings, tendency to overeat, hunger and reactivity to foods in the environment than placebo. Brain imaging pointed the same way, with lower activation to pictures of high-fat, high-sugar food in several regions, though the combined measure for palatable foods did not reach significance. That fits the idea that the medicines act on appetite and reward signalling, and it remains an interpretation of a short trial.

Surveys add the voice of users. The INFORM survey asked 550 US adults on semaglutide to recall their food noise before starting, and their median questionnaire score fell from 13 to 6 out of 20. It relied on memory, had no comparison group, and its authors work for the manufacturer. Treat it as a survey. How the two medicines compare overall is in the Ozempic and Mounjaro head-to-head article, and how tirzepatide works is in the tirzepatide explainer.

What happens when the medicine stops?

Weight is the part that has been tested. In the STEP 1 extension, 327 people were followed for a year after treatment stopped: those who had been on semaglutide regained 11.6 percentage points of body weight, against 1.9 for those who had been on placebo, about two thirds of what the semaglutide group had lost. In SURMOUNT-4, people switched to placebo after 36 weeks of tirzepatide changed by +14.0% over the next 52 weeks, while those who continued changed by -5.5%. The article on weight after stopping goes through those trials and the real-world data.

Whether the thoughts return is a separate question, and the answer is not in those trials. They measured weight and cardiometabolic markers, not food noise. It would be reasonable to expect appetite to rise as weight returns, and that is an inference, not a finding. The studies cited here do not say how fast, how much, or in whom.

Is food noise an eating disorder?

No. Food noise is a description of an experience that many people recognise, and an eating disorder is a diagnosis made by a clinician. They can overlap. The researchers who proposed a definition note that anecdotes of food noise resemble how people with eating disorders describe their thoughts, and that it may occur in them.

A doctor or psychologist is worth seeing for binge eating, eating very little or skipping meals to control weight, making oneself vomit, using laxatives or exercise to compensate, or food thoughts that come with low mood, anxiety or shame. A review of 25 studies of GLP-1 medicines and eating behaviours found limited data on eating disorders, and for most people eating behaviours improved or stayed the same. A weight-loss medicine is not a treatment for an eating disorder, and the assessment should come first. The side effects article covers what else to plan for.

Who decides, and how are these medicines obtained?

Semaglutide and tirzepatide are prescription-only medicines, used after a full evaluation by a doctor. At this clinic GLP-1 medicines are used only after a full assessment with regular follow-up, within medical weight management. Obtaining them without that review carries its own risks, set out in the article on getting GLP-1 medicines legally in Malaysia, and the wider picture of what helps and what does not is in the slimming treatment overview.

The honest complication

The word is ahead of the science. The questionnaire is new, the definition is a proposal, the trials measured cravings and control of eating, and the best-known food noise numbers come from a recall survey. Quieter food thoughts on a medicine are a real report from real people, and they are not yet a measured outcome of a trial. Whether to use a medicine for any reason is a decision made after assessment.

Common questions

What is food noise?

Food noise is a popular term for persistent, intrusive thoughts about food that a person finds unwanted. Researchers describe it as different from ordinary thoughts about meals by its intensity and intrusiveness. It is not a diagnosis, and its definition is still being worked out.

Do Mounjaro and Ozempic reduce food noise?

Trials of semaglutide and tirzepatide show lower cravings, hunger and reactivity to food, and a survey of people on semaglutide reports lower food noise scores. The trials so far measured cravings and hunger rather than food noise itself, so the effect is described as likely and not yet proven.

Does food noise come back when the injection stops?

The withdrawal trials show that weight returns, about two thirds of the loss in the STEP 1 extension. They did not measure food noise, so whether the thoughts return in step with the weight is not established.

Is food noise an eating disorder?

No. It is a description of an experience, and an eating disorder is a diagnosis. The two can overlap, and binge eating, restricting, purging or low mood are reasons to see a doctor or psychologist, with or without a weight-loss medicine.

Sources

  1. Hayashi et al. What Is Food Noise? A Conceptual Model of Food Cue Reactivity. Nutrients 2023;15(22):4809, PMID 38004203 A narrative review prompted by anecdotal reports of less food rumination on GLP-1 medicines; proposes the Cue-Influencer-Reactivity-Outcome (CIRO) model linking food noise to food cue reactivity.
  2. Dhurandhar et al. Food noise: definition, measurement, and future research directions. Nutrition and Diabetes 2025, PMID 40628707 A working definition of persistent thoughts about food perceived as unwanted or distressing, distinguished from routine food thoughts by intensity and intrusiveness; notes the resemblance to how people with eating disorders describe their experience.
  3. Diktas et al. Development and validation of the Food Noise Questionnaire. Obesity 2025;33:289, PMID 39828656 Five-item questionnaire tested in 400 participants, with high internal consistency and test-retest reliability; the authors state its clinical utility still needs study.
  4. Brewis et al. Food noise: conceptual, methodological, and ethical considerations. Appetite 2026;226:108700, PMID 42392316 Commentary on limited evidence for mechanisms, whether food noise is a distinct phenomenon, overlap with existing scales, and the risk of labelling common experiences as pathology.
  5. Wylie et al. Food noise: a theoretical review. Appetite 2026;228:108791, PMID 42772688 The term became popular on social media; little is known about what food noise is or what causes it.
  6. Friedrichsen et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism 2021;23:754, PMID 33269530 Double-blind trial in 72 adults for 20 weeks: 35% lower energy intake at a test lunch, and better control of eating with fewer and weaker food cravings on the Control of Eating Questionnaire.
  7. Wharton et al. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity 2023;31:703, PMID 36655300 In a subgroup of 88 on semaglutide and 86 on placebo, craving control improved at weeks 20, 52 and 104; the P values were not corrected for multiple testing.
  8. Martin et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nature Medicine 2025;31:3141, PMID 40555748 114 adults for 6 weeks: lower appetite, food cravings, tendency to overeat, hunger and reactivity to foods in the environment against placebo; brain imaging showed lower activation to high-fat, high-sugar food photos in several regions but no significant change for the combined palatable-food category.
  9. Arnaut et al. Retrospective assessment of food noise changes after initiation of injectable semaglutide for weight management in the USA: the INFORM survey. Advances in Therapy 2026;43:3649, PMID 42217114 A survey of 550 US adults on semaglutide, 86% women, asked to recall earlier food noise: the median Food Noise Questionnaire score fell from 13 to 6 out of 20. The authors are from the manufacturer of semaglutide.
  10. Wilding et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism 2022;24:1553, PMID 35441470 A year after treatment stopped, in 327 participants: those who had been on semaglutide regained 11.6 percentage points of body weight against 1.9 for those on placebo, about two thirds of the earlier loss.
  11. Aronne et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38, PMID 38078870 670 participants randomised after a 36-week lead-in: weight change from week 36 to 88 was -5.5% on continued tirzepatide and +14.0% on placebo.
  12. Jebeile et al. GLP-1 receptor agonist medications for obesity and type 2 diabetes treatment: a rapid review of changes in eating behaviors and eating disorder risk. Obesity Reviews 2026;27:e70049, PMID 41340366 25 studies; data on eating behaviours and eating disorders are limited, and for most people eating behaviours may improve or stay the same.

If you need more information, you can always contact us.